Jefferies downgraded Deciphera to Hold from Buy with a price target of $25.60, down from $26, after Ono agreed to acquire Deciphera for $25.60 per share in cash. The firm expects the deal to close by Q3, since Ono’s broad cancer pipeline is synergistic and has no real overlap with Deciphera, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds